Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
Status:
Terminated
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Huntington's disease (HD) is a slowly progressive disorder that devastates the lives of those
affected and their families. There are no treatments that slow the progression of HD, only
mildly effective symptomatic therapies are available.Creatine monohydrate is considered a
nutritional supplement. The purpose of CREST-E is to test whether high-dose creatine can slow
the progressive functional decline that occurs in persons 18 years or older with early
clinical features of HD. The long-term safety, tolerability and effectiveness of up to 40
grams daily creatine compared to placebo is studied. A variety of biological processes are
assessed for markers of disease activity or progression and creatine effects. Up to 50 active
research centers globally will enroll 650 subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
National Center for Complementary and Integrative Health (NCCIH) University of Rochester